View in EDS

MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.

Saved in:
Bibliographic Details
Title: MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.
Authors: German B; Department of Surgery, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland.; Walter Reed National Military Medical Center, Bethesda, Maryland.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland.; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Alaiwi SA; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut., Ho KL; Department of Surgery, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland.; Walter Reed National Military Medical Center, Bethesda, Maryland.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland., Nanda JS; Department of Urology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California., Fonseca MA; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Burkhart DL; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Sheahan AV; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Bergom HE; Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, Minnesota., Morel KL; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Hwang JH; Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, Minnesota., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Lawrenson K; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Ellis L; Department of Surgery, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland.; Walter Reed National Military Medical Center, Bethesda, Maryland.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland.; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Source: Cancer research communications [Cancer Res Commun] 2024 Sep 01; Vol. 4 (9), pp. 2295-2307.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39113611
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22German+B%22">German B</searchLink>; Department of Surgery, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland.; Walter Reed National Military Medical Center, Bethesda, Maryland.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland.; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Alaiwi+SA%22">Alaiwi SA</searchLink>; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Ho+KL%22">Ho KL</searchLink>; Department of Surgery, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland.; Walter Reed National Military Medical Center, Bethesda, Maryland.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Nanda+JS%22">Nanda JS</searchLink>; Department of Urology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Fonseca+MA%22">Fonseca MA</searchLink>; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Burkhart+DL%22">Burkhart DL</searchLink>; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Sheahan+AV%22">Sheahan AV</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Bergom+HE%22">Bergom HE</searchLink>; Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, Minnesota.<br /><searchLink fieldCode="AU" term="%22Morel+KL%22">Morel KL</searchLink>; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.<br /><searchLink fieldCode="AU" term="%22Beltran+H%22">Beltran H</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Hwang+JH%22">Hwang JH</searchLink>; Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, Minnesota.<br /><searchLink fieldCode="AU" term="%22Freedman+ML%22">Freedman ML</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Lawrenson+K%22">Lawrenson K</searchLink>; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Ellis+L%22">Ellis L</searchLink>; Department of Surgery, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland.; Walter Reed National Military Medical Center, Bethesda, Maryland.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland.; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918281580506676%22">Cancer research communications</searchLink> [Cancer Res Commun] 2024 Sep 01; Vol. 4 (9), pp. 2295-2307.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918281580506676 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2767-9764 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2227679764%22">27679764 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Res Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39113611
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/2767-9764.CRC-24-0069
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2295
    Titles:
      – TitleFull: MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: German B
      – PersonEntity:
          Name:
            NameFull: Alaiwi SA
      – PersonEntity:
          Name:
            NameFull: Ho KL
      – PersonEntity:
          Name:
            NameFull: Nanda JS
      – PersonEntity:
          Name:
            NameFull: Fonseca MA
      – PersonEntity:
          Name:
            NameFull: Burkhart DL
      – PersonEntity:
          Name:
            NameFull: Sheahan AV
      – PersonEntity:
          Name:
            NameFull: Bergom HE
      – PersonEntity:
          Name:
            NameFull: Morel KL
      – PersonEntity:
          Name:
            NameFull: Beltran H
      – PersonEntity:
          Name:
            NameFull: Hwang JH
      – PersonEntity:
          Name:
            NameFull: Freedman ML
      – PersonEntity:
          Name:
            NameFull: Lawrenson K
      – PersonEntity:
          Name:
            NameFull: Ellis L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2024 Sep 01
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2767-9764
          Numbering:
            – Type: volume
              Value: 4
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Cancer research communications
              Type: main
ResultId 1